Palopegteriparatide Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 1 pharmaceutical company such as ASCENDIS PHARMA BONE. It is marketed under 1 brand name, including YORVIPATH. Available in 3 different strengths, such as EQ 0.168MG TERIPARATIDE/0.56ML (EQ 0.168MG TERIPARATIDE/0.56ML), EQ 0.294MG TERIPARATIDE/0.98ML (EQ 0.294MG TERIPARATIDE/0.98ML), EQ 0.42MG TERIPARATIDE/1.4ML (EQ 0.3MG TERIPARATIDE/ML), and administered through 1 route including SOLUTION;SUBCUTANEOUS.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"130713","ingredient":"PALOPEGTERIPARATIDE","trade_name":"YORVIPATH","family_id":"","publication_number":"US8906847B2","cleaned_patent_number":"8906847","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2031-04-30","publication_date":"2014-12-09","legal_status":"Granted"} US8906847B2 Molecular Formulation 09 Dec, 2014 Granted 30 Apr, 2031
{"application_id":"130715","ingredient":"PALOPEGTERIPARATIDE","trade_name":"YORVIPATH","family_id":"","publication_number":"US11759504B2","cleaned_patent_number":"11759504","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-09-28","publication_date":"2023-09-19","legal_status":"Granted"} US11759504B2 Formulation 19 Sep, 2023 Granted 28 Sep, 2037
{"application_id":"130711","ingredient":"PALOPEGTERIPARATIDE","trade_name":"YORVIPATH","family_id":"","publication_number":"US11857603B2","cleaned_patent_number":"11857603","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-09-28","publication_date":"2024-01-02","legal_status":"Granted"} US11857603B2 02 Jan, 2024 Granted 28 Sep, 2037
{"application_id":"130712","ingredient":"PALOPEGTERIPARATIDE","trade_name":"YORVIPATH","family_id":"","publication_number":"US11590207B2","cleaned_patent_number":"11590207","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-09-28","publication_date":"2023-02-28","legal_status":"Granted"} US11590207B2 28 Feb, 2023 Granted 28 Sep, 2037
{"application_id":"130716","ingredient":"PALOPEGTERIPARATIDE","trade_name":"YORVIPATH","family_id":"","publication_number":"US11918628B2","cleaned_patent_number":"11918628","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-09-28","publication_date":"2024-03-05","legal_status":"Granted"} US11918628B2 Molecular Formulation 05 Mar, 2024 Granted 28 Sep, 2037
{"application_id":"242140","ingredient":"PALOPEGTERIPARATIDE","trade_name":"YORVIPATH","family_id":"","publication_number":"US12295989B2","cleaned_patent_number":"12295989","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-09-28","publication_date":"2025-05-13","legal_status":"Granted"} US12295989B2 13 May, 2025 Granted 28 Sep, 2037
{"application_id":"130714","ingredient":"PALOPEGTERIPARATIDE","trade_name":"YORVIPATH","family_id":"","publication_number":"US11890326B2","cleaned_patent_number":"11890326","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2037-09-28","publication_date":"2024-02-06","legal_status":"Granted"} US11890326B2 Molecular Formulation 06 Feb, 2024 Granted 28 Sep, 2037

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Palopegteriparatide

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.